SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

HC Wainwright & Co. Initiates Coverage On Fate Therapeutics with Buy Rating, Announces Price Target of $42

HC Wainwright & Co. initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and announces Price Target of $42.

Benzinga · 05/13/2020 11:30

HC Wainwright & Co. initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Buy rating and announces Price Target of $42.